Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Blanca Elí Ocampo-García is active in the Biotechnology & Pharmaceuticals technology area. The current data indicates a narrow prosecution footprint, with 1 pending office action across the entire portfolio. This 1 pending office action suggests that the current interactions with the USPTO are highly centralized for this applicant.
The portfolio's activity is restricted to 1 distinct examiner and 1 distinct art unit. The busiest examiner identified in the data is CABRAL, ROBERT S, who is currently handling 1 pending office action. This concentration within 1 distinct art unit implies that the subject matter of the pending application is technically focused within the Biotechnology & Pharmaceuticals field.
For a patent practitioner, the presence of 1 distinct examiner means that the prosecution strategy does not need to account for divergent examiner behaviors. The fact that CABRAL, ROBERT S is the only examiner with a pending action simplifies the communication and negotiation process. This focused approach allows for a more targeted response to the 1 pending office action currently on the docket.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CABRAL, ROBERT S | 1 | 62.8% | +32.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288838 | RADIOPHARMACEUTICALS BASED ON ((R)-1-((6-HYDRAZINYLNICOTINOYL)-D-ALANYL)PYRROLIDIN-2-YL)BORONIC ACID (HYNIC-IFAP) FOR DETECTING THE OVEREXPRESSION OF FIBROBLAST ACTIVATION PROTEIN | CABRAL, ROBERT S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18288838 | RADIOPHARMACEUTICALS BASED ON ((R)-1-((6-HYDRAZINYLNICOTINOYL)-D-ALANYL)PYRROLIDIN-2-YL)BORONIC ACID (HYNIC-IFAP) FOR DETECTING THE OVEREXPRESSION OF FIBROBLAST ACTIVATION PROTEIN | CABRAL, ROBERT S | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18288838 | RADIOPHARMACEUTICALS BASED ON ((R)-1-((6-HYDRAZINYLNICOTINOYL)-D-ALANYL)PYRROLIDIN-2-YL)BORONIC ACID (HYNIC-IFAP) FOR DETECTING THE OVEREXPRESSION OF FIBROBLAST ACTIVATION PROTEIN | CABRAL, ROBERT S | 1614 | §102§103 | Final Rejection | — | Pending | Oct 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBlanca Elí Ocampo-García has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert S Cabral has the most, with 1 of Blanca Elí Ocampo-García's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
